Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-7904L in advanced head and neck cancer
NCT00116909Phase 2Completed
- Sponsor
- OSI Pharmaceuticals
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of OSI-7904L in squamous cell carcinoma of the head and neck (HNSCC), sponsored by OSI Pharmaceuticals. Primary endpoint: Efficacy. Started Aug 2004; status: completed.
02
Drugs
OSI-7904L
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00116909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00116909.